These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2568929)

  • 1. Pharmacokinetics of famotidine in elderly patients with and without renal insufficiency and in healthy young volunteers.
    Inotsume N; Nishimura M; Fujiyama S; Sagara K; Sato T; Imai Y; Matsui H; Nakano M
    Eur J Clin Pharmacol; 1989; 36(5):517-20. PubMed ID: 2568929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.
    Lin JH; Chremos AN; Yeh KC; Antonello J; Hessey GA
    Eur J Clin Pharmacol; 1988; 34(1):41-6. PubMed ID: 2896129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.
    Takabatake T; Ohta H; Maekawa M; Yamamoto Y; Ishida Y; Hara H; Nakamura S; Ushiogi Y; Kawabata M; Hashimoto N
    Eur J Clin Pharmacol; 1985; 28(3):327-31. PubMed ID: 2861096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of famotidine in man.
    Kroemer H; Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1987 Aug; 25(8):458-63. PubMed ID: 2888738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of famotidine on renal function in patients with renal insufficiency.
    Abraham PA; Opsahl JA; Halstenson CE; Chremos AN; Matzke GR; Keane WF
    Br J Clin Pharmacol; 1987 Sep; 24(3):385-9. PubMed ID: 2889461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.
    Lin JH
    Clin Pharmacokinet; 1991 Mar; 20(3):218-36. PubMed ID: 1673880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disposition of famotidine in renal insufficiency.
    Halstenson CE; Abraham PA; Opsahl JA; Chremos AN; Keane WF; Matzke GR
    J Clin Pharmacol; 1987 Oct; 27(10):782-7. PubMed ID: 3429684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies.
    Yeh KC; Chremos AN; Lin JH; Constanzer ML; Kanovsky SM; Hucker HB; Antonello J; Vlasses P; Ryan JR; Williams RL
    Biopharm Drug Dispos; 1987; 8(6):549-60. PubMed ID: 2892544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Famotidine pharmacokinetics following oral and intravenous administration in patients with liver disease: results of a preliminary study.
    Morgan MY; Stambuk D
    Postgrad Med J; 1986; 62 Suppl 2():29-37. PubMed ID: 2890149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Famotidine disposition in children and adolescents with chronic renal insufficiency.
    Maples HD; James LP; Stowe CD; Jones DP; Hak EB; Blumer JL; Vogt B; Wilson JT; Kearns GL; Wells TG;
    J Clin Pharmacol; 2003 Jan; 43(1):7-14. PubMed ID: 12520622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nizatidine, and H2-receptor antagonist: disposition and safety in the elderly.
    Callaghan JT; Rubin A; Knadler MP; Bergstrom RF
    J Clin Pharmacol; 1987 Aug; 27(8):618-24. PubMed ID: 2888796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nizatidine disposition in subjects with normal and impaired renal function.
    Aronoff GR; Bergstrom RF; Bopp RJ; Sloan RS; Callaghan JT
    Clin Pharmacol Ther; 1988 Jun; 43(6):688-95. PubMed ID: 2897890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and dynamics of famotidine in patients with renal failure.
    Gladziwa U; Klotz U; Krishna DR; Schmitt H; Glöckner WM; Mann H
    Br J Clin Pharmacol; 1988 Sep; 26(3):315-21. PubMed ID: 2902874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Famotidine, a new H2-receptor antagonist, does not affect hepatic elimination of diazepam or tubular secretion of procainamide.
    Klotz U; Arvela P; Rosenkranz B
    Eur J Clin Pharmacol; 1985; 28(6):671-5. PubMed ID: 2866097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal therapeutic regimen of famotidine based on plasma concentrations in patients with chronic renal failure.
    Hachisu T; Yokoyama T; Oda Y; Ando K; Hattori Y; Yoshida T
    Clin Ther; 1988; 10(6):656-63. PubMed ID: 2905936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of histamine (H2)-receptor antagonists, including roxatidine, in chronic renal failure.
    Lameire N; Rosenkranz B; Brockmeier D
    Scand J Gastroenterol Suppl; 1988; 146():100-10. PubMed ID: 2906455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects.
    Echizen H; Shoda R; Umeda N; Ishizaki T
    Clin Pharmacol Ther; 1988 Dec; 44(6):690-8. PubMed ID: 2904311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers.
    Lin JH; Chremos AN; Chiou R; Yeh KC; Williams R
    Br J Clin Pharmacol; 1987 Nov; 24(5):669-72. PubMed ID: 2893637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of diazepam with famotidine and cimetidine, two H2-receptor antagonists.
    Locniskar A; Greenblatt DJ; Harmatz JS; Zinny MA; Shader RI
    J Clin Pharmacol; 1986 Apr; 26(4):299-303. PubMed ID: 2871051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antacids and food on absorption of famotidine.
    Lin JH; Chremos AN; Kanovsky SM; Schwartz S; Yeh KC; Kann J
    Br J Clin Pharmacol; 1987 Oct; 24(4):551-3. PubMed ID: 2891370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.